Most Recent
The majority shareholders of vitamin giant Nature’s Care have been hit with the costs of the company’s failed bid for an injunction against its founding family, after a judge found the shareholders appear to have caused proceedings to be commenced as part of a strategy to “override the rights” of the family.
The state of Victoria has won its bid to prevent lawyers for a class action over Victoria's COVID-19 hotel quarantine debacle from proofing lay witnesses, ahead of a criminal trial against the Department of Health, which is due to start in May.
US animal drug manufacturer Zoetis has been granted leave to appeal a ruling that invalidated three of its patents covering pig vaccines.
Indian generics company Sun Pharma has taken Otsuka Pharmaceutical to court, alleging an extension for the patent for an injectable form of the Japanese drug maker's blockbuster antipsychotic Abilify was wrongly granted and should be invalidated.
A judge has railed against the parties in a class action against Sydney-based plastic surgeon Daniel Lanzer and four of his associates for “repeated failure to comply with court orders” in the two-year-old case.
Victoria's Peninsula Health has abandoned an appeal of a ruling in a class action that found it breached workplace laws by failing to pay overtime to a junior doctor, a capitulation that could be a game changer for a series of class actions against health care providers.
Twenty-six emergency doctors have brought an underpayments lawsuit against Melbourne hospital operator Austin Health, claiming that for the past six year they have not been paid the full amount they are owed.
The current owners of vitamin giant Nature’s Care have lost a bid to extend an urgent injunction against the company’s founding family amid fears they were trying to regain control of the corporate group, with a judge finding the family may faced oppressive conduct themselves.
A nose job patient who allegedly defamed his surgeon has been slugged with $50,000 in security for his appeal, on top of a $50,000 damages bill that a judge said the surgeon is unlikely to see.
South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson's Janssen Biotech to invalidate two patents for Crohn's disease drug Stelara, after reaching a licencing agreement over the medicine in the US.